The wrong strategy could mean delays, rework, or even market withdrawal
Recent Developments GLP-1 Market (2025-2026) In June 2026 , Novo Nordisk and Eli Lilly introduced GLP-1 pills for obesity, and their competition at the American Diabetes Association (ADA) Scientific Sessions
And this all this all gets credited to a beautiful paper review paper that, uh, Dr
Proc Natl Acad Sci U S A , 109 (38), 1510115108
The real question, and the one that matters most to compounders in the near term, is whether the FDA will extend enforcement discretion to these substances, allowing them to be compounded under the interim policy while the formal rulemaking process plays out
Il protge galement lorganisme des personnes ayant dimportants problmes lis au sucre contre les complications de ceux-ci long terme (comme la diminution de la vision, les infections, les problmes circulatoires, cardiaques et rnaux)